CMX001 Prevents CMV Disease in Transplant Recipients

This novel agent — 100 mg twice weekly — was effective in preventing cytomegalovirus disease in hematopoietic-cell transplant recipients, with no evidence of myelosuppression or nephrotoxicity.

A safe, effective regimen is needed for the prevention and control of cytomegalovirus (CMV) infection in allogeneic hematopoietic-cell transplant recipients. A novel, orally bioavailable agent, CMX001, is of keen interest because it is converted intracellularly to cidofovir but is not concentrated in the renal tubules like cidofovir and is thus less likely to have nephrotoxicity. Moreover, CMX001 is approximately 400 times more potent than cidofovir against CMV (including ganciclovir-resistant strains) in vitro and is effective against CMV disease in animal models. In a recent manufacturer-funded, randomized, placebo-controlled trial, researchers evaluated its safety and anti-CMV activity in humans.

CMV-seropositive allogeneic hematopoietic-…

Reviewing Author

Larry M. Baddour, MD

Disclosures

RoyaltiesUpToDate, Inc. (Authorship duties)

Larry M. Baddour, MD

Disclosures

RoyaltiesUpToDate, Inc. (Authorship duties)

CMX001 Prevents CMV Disease in Transplant Recipients

Topics

Reviewing Author